<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516317</url>
  </required_header>
  <id_info>
    <org_study_id>P20/18_Palustar</org_study_id>
    <nct_id>NCT04516317</nct_id>
  </id_info>
  <brief_title>Very Severe Malaria Treated by Intravenous Artesunate</brief_title>
  <acronym>Palustar</acronym>
  <official_title>Very Severe Malaria Treated by Intravenous Artesunate: Epidemiology, Management, Outcome and Prognostic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Fabrice BRUNEEL</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In endemic areas, Plasmodium falciparum malaria exacts a huge public health toll, causing&#xD;
      close to half a million deaths each year. In non-endemic industrialized areas, imported&#xD;
      malaria may develop. In France, around 5000 imported cases occured annually, including 10-15%&#xD;
      of severe malaria.&#xD;
&#xD;
      The criteria for defining severe malaria in endemic areas are established by the World Health&#xD;
      Organization (WHO), and have been adjusted for severe imported malaria. In France, in order&#xD;
      to optimize management, severe imported malaria is separated into two groups: very severe&#xD;
      malaria (VSM) and less severe malaria (LSM). Briefly VSM included coma and/or shock and/or&#xD;
      respiratory failure and/or acidosis and/or hyperlactatemia and/or death during&#xD;
      hospitalization.&#xD;
&#xD;
      In France, severe imported malaria is treated with intravenous artesunate. Little is known&#xD;
      about the management of imported VSM in the ICU with intravenous artesunate.&#xD;
&#xD;
      In a French national multicentric retrospective frame, the main objective of the present&#xD;
      study is to describe in detail: epidemiology, management, outcome and prognostic of very&#xD;
      severe imported malaria treated with intravenous artesunate during the period 2011-2019. The&#xD;
      second objective is to retrospectively compare two groups : VSM treated with intravenous&#xD;
      artesunate in the ICU during 2011-2019 versus VSM treated with intravenous quinine in the ICU&#xD;
      during 2000-2010.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See Brief Summary&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate in the Group intravenous artesunate</measure>
    <time_frame>At hospital discharge, an average of 1 month</time_frame>
    <description>Mortality reported as a mortality rate (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rates in the Group artesunate and Group quinine</measure>
    <time_frame>At hospital discharge, an average of 1 month</time_frame>
    <description>Mortality reported as a mortality rate (%)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Severe Malaria</condition>
  <arm_group>
    <arm_group_label>Group intravenous artesunate (around 300 patients)</arm_group_label>
    <description>Period 2011-2019</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group intravenous quinine (around 300 patients)</arm_group_label>
    <description>Period 2000-2010</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None (Observational study Group intravenous artesunate)</intervention_name>
    <description>Retrospective descriptive study of Group intravenous artesunate</description>
    <arm_group_label>Group intravenous artesunate (around 300 patients)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>None (Observational study Group intravenous quinine)</intervention_name>
    <description>Retrospective descriptive study of Group intravenous quinine</description>
    <arm_group_label>Group intravenous quinine (around 300 patients)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Very severe malaria in adults / Antimalarial treatment (Artesunate period 2011-2019 ;&#xD;
        Quinine period 2000-2010)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than 18 year-old at the time of inclusion AND&#xD;
&#xD;
          -  Hospitalization in the ICU AND&#xD;
&#xD;
          -  For severe imported malaria (Plasmodium falciparum) AND&#xD;
&#xD;
          -  Very Severe Malaria episode defined during the 72 first hours as :&#xD;
&#xD;
               -  Neurological failure: Glasgow Coma Scale score&lt;11 or repeated convulsions and/or&#xD;
&#xD;
               -  Shock: Systolic Blood Pressure&lt;80 mmHg despite adequate fluid loading or need for&#xD;
                  vasoactive drugs and/or&#xD;
&#xD;
               -  Respiratory distress: Mechanical Ventilation or Non Invasive Ventilation ; or if&#xD;
                  spontaneous breathing: arterial pO2&lt;60 mmHg or pulse oxymetry&lt;92% in room air ;&#xD;
                  or Respiratory Rate&gt;32/min and/or&#xD;
&#xD;
               -  Acidosis: plasma bicarbonate &lt;15 mmol/l, or pH&lt;7,35 and/or&#xD;
&#xD;
               -  Hyperlactatemia &gt; 5 mmol/l and/or&#xD;
&#xD;
               -  Death during hospitalization for VSM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 year-old at the time of inclusion OR&#xD;
&#xD;
          -  Opposition to participate in the present study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice BRUNEEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Versailles Hospital Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice BRUNEEL, MD</last_name>
    <phone>+33 139639058</phone>
    <email>fbruneel@ch-versailles.fr</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Dr Fabrice BRUNEEL</investigator_full_name>
    <investigator_title>Investigator MD</investigator_title>
  </responsible_party>
  <keyword>Severe Malaria</keyword>
  <keyword>Artesunate</keyword>
  <keyword>Critical Care</keyword>
  <keyword>Quinine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Quinine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

